Stock A002390 HANDOK INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News HANDOK Inc.

Equities

A002390

KR7002390003

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 02/06/2024 BST 		5-day change 1st Jan Change
15,800 KRW +1.41% Intraday chart for HANDOK Inc. -5.22% +10.49%
05-24 Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea MT
05-24 Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea
MT
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc
CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,
MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea
CI
Sobi and Handok establish joint venture for rare disease business in South Korea
AQ
Sobi to Expand in South Korea via Rare Disease JV with Handok
MT
HANDOK Inc.(KOSE:A002390) dropped from S&P Global BMI Index
CI
HANDOK Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Rezolute Unveils Plans for Secondary Offering of 3.24 Million Shares
MT
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency
MT
AUM Biosciences Enters in A Strategic Collaboration with Handok and CMG Pharm to Develop ‘CHC2014’, New Pan-TRK Inhibitor for Cancer Treatment
CI
WELT Corp., Ltd announced that it has received KRW 6 billion in funding from HANDOK Inc., Smilegate Investment, Inc., POSCO Venture Capital Co., Ltd.
CI
Adicet Bio, Inc. announced that it has received $80 million in funding from a group of investors
CI
Rezolute, Inc. announced that it has received $24.05 million in funding from Genexine, Inc., Handok, Inc., District 2 Capital Fund LP, The Bigger Capital Fund, LP and another investor
CI
Adicet Bio, Inc. announced that it expects to receive $80 million in funding
CI
Rezolute, Inc. announced that it expects to receive $20.25 million in funding from District 2 Capital Fund LP, The Bigger Capital Fund, LP, Genexine, Inc., Handok, Inc.
CI
TRIGR Therapeutics, Inc announced that it has received $14 million in funding from Handok Inc.
CI
BiomX Ltd announced that it has received $32 million in funding from a group of investors
CI
Rezolute, Inc. announced that it has received $25 million in funding from Genexine, Inc., Handok, Inc.
CI
Rezolute, Inc. announced that it expects to receive $25 million in funding from Genexine, Inc., Handok Inc.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A002390 Stock
  4. News HANDOK Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW